BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review.

ABSTRACT:

Introduction

The Bruton tyrosine kinase (BTK) regulates B cell and macrophage signaling, development, survival, and activation. Inhibiting BTK has been hypothesized to ameliorate lung injury in patients with severe COVID-19, however clinical outcome data is inconclusive.

Objective

To evaluate the clinical outcomes of BTK inhibitors (BTKinibs) in patients with COVID-19.

Evidence review

We searched PubMed, Embase, and Web of Science:Core on December 30, 2020. Clinical studies with at least 5 COVID-19 patients treated with BTKinibs were included. Case reports and reviews were excluded.

Findings

125 articles were identified, 6 of which met inclusion criteria. The most common clinical outcomes measured were oxygen requirements (4/6) and hospitalization rate or durat

SUBMITTER: Stack M 

PROVIDER: S-EPMC8327577 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature